[go: up one dir, main page]

FI960892L - Polymeerimatriisit ja niiden käyttö farmaseuttisissa koostumuksissa - Google Patents

Polymeerimatriisit ja niiden käyttö farmaseuttisissa koostumuksissa Download PDF

Info

Publication number
FI960892L
FI960892L FI960892A FI960892A FI960892L FI 960892 L FI960892 L FI 960892L FI 960892 A FI960892 A FI 960892A FI 960892 A FI960892 A FI 960892A FI 960892 L FI960892 L FI 960892L
Authority
FI
Finland
Prior art keywords
pharmaceutical compositions
polymer matrices
matrices
polymer
pharmaceutical
Prior art date
Application number
FI960892A
Other languages
English (en)
Swedish (sv)
Other versions
FI960892A7 (fi
FI960892A0 (fi
Inventor
Murat Acemoglu
Siegfried Bantle
David Bodmer
Salvatore Cammisuli
Peter Hiestand
Fritz Nimmerfall
Georg Stoll
Original Assignee
Sandoz Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939317822A external-priority patent/GB9317822D0/en
Priority claimed from GB939320240A external-priority patent/GB9320240D0/en
Priority claimed from GB939325900A external-priority patent/GB9325900D0/en
Priority claimed from GB9407156A external-priority patent/GB9407156D0/en
Application filed by Sandoz Ltd filed Critical Sandoz Ltd
Publication of FI960892A0 publication Critical patent/FI960892A0/fi
Publication of FI960892A7 publication Critical patent/FI960892A7/fi
Publication of FI960892L publication Critical patent/FI960892L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G64/00—Macromolecular compounds obtained by reactions forming a carbonic ester link in the main chain of the macromolecule
    • C08G64/18—Block or graft polymers
    • C08G64/183—Block or graft polymers containing polyether sequences
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G64/00—Macromolecular compounds obtained by reactions forming a carbonic ester link in the main chain of the macromolecule
    • C08G64/02—Aliphatic polycarbonates
    • C08G64/0208—Aliphatic polycarbonates saturated
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G64/00—Macromolecular compounds obtained by reactions forming a carbonic ester link in the main chain of the macromolecule
    • C08G64/20—General preparatory processes
    • C08G64/32—General preparatory processes using carbon dioxide
    • C08G64/34—General preparatory processes using carbon dioxide and cyclic ethers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI960892A 1993-08-27 1994-08-26 Polymeerimatriisit ja niiden käyttö farmaseuttisissa koostumuksissa FI960892L (fi)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB939317822A GB9317822D0 (en) 1993-08-27 1993-08-27 Organic compounds
GB939320240A GB9320240D0 (en) 1993-10-01 1993-10-01 Improvements in or relating to organic compounds
GB939325900A GB9325900D0 (en) 1993-12-17 1993-12-17 Organic compounds
GB9407156A GB9407156D0 (en) 1994-04-11 1994-04-11 Organic compounds
PCT/EP1994/002833 WO1995006077A2 (en) 1993-08-27 1994-08-26 Polymeric matrices and their uses in pharmaceutical compositions

Publications (3)

Publication Number Publication Date
FI960892A0 FI960892A0 (fi) 1996-02-26
FI960892A7 FI960892A7 (fi) 1996-04-18
FI960892L true FI960892L (fi) 1996-04-18

Family

ID=27451062

Family Applications (1)

Application Number Title Priority Date Filing Date
FI960892A FI960892L (fi) 1993-08-27 1994-08-26 Polymeerimatriisit ja niiden käyttö farmaseuttisissa koostumuksissa

Country Status (24)

Country Link
US (2) US6083521A (fi)
EP (2) EP0719295B1 (fi)
JP (2) JP3343124B2 (fi)
KR (1) KR100341995B1 (fi)
CN (3) CN1085687C (fi)
AT (1) ATE327273T1 (fi)
AU (1) AU697995B2 (fi)
BR (1) BR9407370A (fi)
CA (1) CA2168012C (fi)
CZ (1) CZ55296A3 (fi)
DE (1) DE69434743T2 (fi)
DK (1) DK0719295T3 (fi)
ES (1) ES2262135T3 (fi)
FI (1) FI960892L (fi)
HU (1) HU220637B1 (fi)
IL (1) IL110787A0 (fi)
NO (2) NO960721L (fi)
NZ (1) NZ273319A (fi)
PL (1) PL182569B1 (fi)
PT (1) PT719295E (fi)
SG (2) SG87847A1 (fi)
SK (1) SK25496A3 (fi)
TW (1) TW492863B (fi)
WO (1) WO1995006077A2 (fi)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US6756060B1 (en) 1996-09-19 2004-06-29 Usbiomaterials Corp. Anti-inflammatory and antimicrobial uses for bioactive glass compositions
GB9725480D0 (en) * 1997-12-01 1998-01-28 Univ London Cytokines and their use in the treatment of established chronic infections and cancers
US8197430B1 (en) 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
US6620382B1 (en) 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US6100372A (en) * 1998-08-20 2000-08-08 Akzo Nobel Nv Monocarboxylic acid-terminated polymers of carbon dioxide and an alkylene oxide
JP2002543108A (ja) * 1999-04-29 2002-12-17 ユーエスバイオマテリアルズ コーポレイション 抗炎症性生物活性ガラス微粒子
AU5485200A (en) 1999-06-14 2001-01-02 Imperial College Innovations Silver-containing, sol-gel derived bioglass compositions
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
MXPA03001142A (es) * 2000-08-11 2004-08-02 Favrille Inc Metodo y composicion para alterar una patologia mediada por celulas t.
AU2001288829A1 (en) * 2000-09-06 2002-03-22 Ap Pharma, Inc. Degradable polyacetal polymers
US6590059B2 (en) * 2001-05-11 2003-07-08 Ap Pharma, Inc. Bioerodible polyorthoesters from dioxolane-based diketene acetals
US20030152630A1 (en) * 2001-05-11 2003-08-14 Ng Steven Y. PEG-POE, PEG-POE-PEG, and POE-PEG-POE block copolymers
JP2005516586A (ja) * 2001-07-20 2005-06-09 ボード オブ トラスティーズ オブ ザ ユニヴァースティ オブ イリノイ 癌の処置に対する遺伝子標的を同定するための試薬および方法
US7658926B2 (en) * 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods
US6524606B1 (en) * 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups
US20030216315A1 (en) 2002-02-13 2003-11-20 Duke University Modulation of immune response by non-peptide binding stress response polypeptides
AU2003222660A1 (en) * 2002-04-18 2003-11-03 Robert S. Langer Biodegradable shape memory polymeric sutures
EP2363710B1 (en) * 2002-08-08 2015-07-01 Baylor College Of Medicine Isolation and identification of T cells
WO2004030631A2 (en) 2002-10-01 2004-04-15 Chiron Corporation Anti-cancer and anti-infectious disease compositions and methods for using same
GB0228571D0 (en) * 2002-12-06 2003-01-15 Novartis Ag Organic compounds
AU2004308654B2 (en) * 2003-12-24 2008-11-20 Novartis Ag Pharmaceutical Compositions
CN100571793C (zh) * 2003-12-24 2009-12-23 诺瓦提斯公司 药物组合物
CA2565215C (en) * 2004-04-30 2014-04-15 Biopheresis Technologies, Inc. Method and system to remove soluble tnfr1, tnfr2, and il2 in patients
WO2006078320A2 (en) 2004-08-04 2006-07-27 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
JP4870071B2 (ja) * 2005-03-18 2012-02-08 三井化学株式会社 生分解性を有する水環境応答型ポリマー、その製造方法および水崩壊性材料
US20070099867A1 (en) * 2005-05-24 2007-05-03 Glycoscience Laboratories, Inc. Pharmaceutical agent containing hyaluronan as an active ingredient
DK1787658T3 (da) 2005-11-10 2012-06-25 Chemi Spa Formuleringer med forsinket frigørelse og indeholdende somatostatin-analoge væksthormoninhibitorer
EP2016414B1 (en) * 2006-05-05 2015-09-02 Opexa Therapeutics T-cell vaccine
JP5419699B2 (ja) * 2006-10-31 2014-02-19 エボニック コーポレイション 球状化されたポリマー粒子
US8728528B2 (en) 2007-12-20 2014-05-20 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
PT2337809T (pt) 2008-09-08 2017-11-14 Saudi Aramco Tech Co Composições de policarbonato-poliol e métodos
WO2010079052A2 (en) * 2008-12-15 2010-07-15 Novartis Ag Nanoparticle compositions
US8716204B2 (en) 2010-07-27 2014-05-06 Zimmer, Inc. Synthetic synovial fluid compositions and methods for making the same
EP2736974B1 (en) 2011-07-25 2019-07-10 Saudi Aramco Technologies Company Polymer compositions and methods
TR201202779A2 (tr) 2012-03-12 2013-10-21 Petkim Petrokimya Holding Anonim Sirketi Polietilen karbonat üretim yöntemi.
EP2664641B1 (en) 2012-05-18 2018-04-25 Petkim Petrokimya Holding Anonim Sirekti Method for producing polyethylene carbonate with metal salts
US9388277B2 (en) * 2012-05-24 2016-07-12 Novomer, Inc. Polycarbonate polyol compositions and methods
WO2014074706A1 (en) 2012-11-07 2014-05-15 Novomer, Inc. High strength polyurethane foam compositions and methods
BR112017018954A2 (pt) 2015-03-06 2018-05-15 Beyondspring Pharmaceuticals, Inc. uso de forma mutante de proteína ras e método para tratar câncer
ES2910035T3 (es) 2015-07-13 2022-05-11 Beyondspring Pharmaceuticals Inc Composiciones de plinabulina
CN108778267A (zh) 2016-02-08 2018-11-09 万春药业公司 包含妥卡雷琐或其类似物的组合物
MX389200B (es) 2016-06-06 2025-03-20 Beyondspring Pharmaceuticals Inc Composición y método para reducir la neutropenia.
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
MX2019009020A (es) 2017-02-01 2019-11-12 Beyondspring Pharmaceuticals Inc Metodo para reducir la neutropenia.
AU2019212118A1 (en) * 2018-01-24 2020-09-03 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
WO2020028606A1 (en) 2018-08-02 2020-02-06 Saudi Aramco Technologies Company Sustainable polymer compositions and methods
JP7433606B2 (ja) * 2019-12-16 2024-02-20 帝人株式会社 コポリマー材料およびそれからなる医療用成形品
US20240197723A1 (en) 2021-04-09 2024-06-20 Beyondspring Pharmaceuticals, Inc. Therapeutic compositions and methods for treating tumors
JP2024525422A (ja) 2021-06-23 2024-07-12 サウジ アラムコ テクノロジーズ カンパニー ポリオール組成物及び方法
CN121401211A (zh) * 2024-02-29 2026-01-27 珠海市华海康医药科技有限责任公司 一种双羟萘酸盐药物缓释微球及其制备方法
CN119505213B (zh) * 2024-11-25 2025-12-09 吉林大学 一种聚碳酸酯聚合物及其制备方法、纳米佐剂和疫苗

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3585168A (en) * 1968-09-21 1971-06-15 Shohei Inoue Process for producing copolymer of epoxide and carbon dioxide
US3706713A (en) * 1970-08-11 1972-12-19 Shell Oil Co Aliphatic polycarbonates
JPS5341117B2 (fi) * 1971-12-21 1978-10-31
US3953383A (en) * 1972-07-21 1976-04-27 Nippon Oil Seal Industry Co., Ltd. Catalytic process for copolymerizing epoxy compounds with carbon dioxide
JPS553288B2 (fi) * 1973-08-06 1980-01-24
JPS5761769B2 (fi) * 1974-03-20 1982-12-25 Nippon Oil Seal Ind Co Ltd
JPS5922731B2 (ja) * 1975-09-12 1984-05-29 エヌオーケー株式会社 共重合用触媒の製造法
JPS5438397A (en) * 1977-08-31 1979-03-22 Hidetoshi Tsuchida Copolymerization catalyst consisting of carbon dioxide and oxirane compoud
US4379138A (en) * 1981-12-28 1983-04-05 Research Triangle Institute Biodegradable polymers of lactones
NZ217844A (en) * 1985-10-11 1989-10-27 Sumitomo Pharma A sustained release pharmaceutical composition containing silicone elastomer and an albumin
JPH0725688B2 (ja) * 1986-03-31 1995-03-22 住友製薬株式会社 Ｃｓｆ徐放性製剤
US4665136A (en) * 1986-04-07 1987-05-12 Air Products And Chemicals, Inc. Process for producing novel block alkylene polycarbonate copolymers
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
JPH0725689B2 (ja) * 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
US5114719A (en) * 1987-04-29 1992-05-19 Sabel Bernhard A Extended drug delivery of small, water-soluble molecules
US4783445A (en) * 1987-12-14 1988-11-08 Arco Chemical Company Soluble epoxide/carbon dioxide copolymerization catalysts
WO1989005664A1 (en) * 1987-12-17 1989-06-29 Allied-Signal Inc. Medical devices fabricated from homopolymers and copolymers having recurring carbonate units
US5274074A (en) * 1987-12-17 1993-12-28 United States Surgical Corporation Medical devices fabricated from homopolymers and copolymers having recurring carbonate units
US4789727A (en) * 1987-12-18 1988-12-06 Arco Chemical Company Reduction of catalyst usage in epoxide/CO2 polymerization
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
EP0358326B1 (en) * 1988-08-09 1996-12-27 Mitsui Petrochemical Industries, Ltd. Process for preparing a zinc-containing solid catalyst and process for preparing polyalkylene carbonate
EP0374510B1 (en) * 1988-12-19 1997-01-15 American Cyanamid Company Products for the treatment of endotoxic shock in a mammal
JPH04503607A (ja) * 1989-02-24 1992-07-02 イムノセラピューティックス・インコーポレイテッド 固定化サイトカイン類
US4999417A (en) * 1989-03-30 1991-03-12 Nova Pharmaceutical Corporation Biodegradable polymer compositions
US4960862A (en) * 1989-03-31 1990-10-02 Air Products And Chemicals, Inc. Regeneration of metallo-organic catalyst for carbon dioxide-epoxide copolymerization
US5026676A (en) * 1989-06-07 1991-06-25 Air Products And Chemicals, Inc. Catalyst for the copolymerization of epoxides with CO2
US4943677A (en) * 1989-06-08 1990-07-24 Air Products And Chemicals, Inc. Making poly(alkylene carbonates) of controlled molecular weight
JP2693584B2 (ja) * 1989-06-26 1997-12-24 三井石油化学工業株式会社 ポリアルキレンカーボネート製造用触媒成分の製造方法
US5126147A (en) * 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
JP2930362B2 (ja) * 1990-04-09 1999-08-03 東ソー株式会社 感作ｔ細胞関与疾患の治療剤
ATE104826T1 (de) * 1990-07-02 1994-05-15 Bend Res Inc Asymmetrische mikroporoese kuegelchen fuer regulierbare freigabe.
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
EP0486437B1 (en) * 1990-11-13 1997-07-09 ISTITUTO SIEROVACCINOGENO ITALIANO I.S.I. S.p.A. Functional polyesters from glycidyl derivatives and cyclic anhydrides or carbon dioxide
CA2099376A1 (en) * 1991-01-03 1992-07-04 Henry E. Auer Stabilization of proteins by cationic biopolymers
CA2060635A1 (en) * 1991-02-12 1992-08-13 Keith D'alessio Bioabsorbable medical implants
IT1248061B (it) * 1991-06-14 1995-01-05 Mediolanum Farmaceutici Spa Policarbonati e loro uso per la preparazione di matrici bioerodibili
US5344644A (en) * 1991-08-01 1994-09-06 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release
ATE154241T1 (de) * 1991-10-01 1997-06-15 Takeda Chemical Industries Ltd Mikropartikeln-zusammenfassung zur verlängerten freigabe und herstellung derselbe
AU3244693A (en) * 1991-12-17 1993-07-19 Schering Corporation Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock
JPH05194253A (ja) * 1992-01-16 1993-08-03 Kirin Brewery Co Ltd 水溶性ポリペプチドホルモンを含む徐放性微小粒子状製剤及びその製造法
GB9206736D0 (en) * 1992-03-27 1992-05-13 Sandoz Ltd Improvements of organic compounds and their use in pharmaceutical compositions
ZA933926B (en) * 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
GB9406094D0 (en) * 1994-03-28 1994-05-18 Univ Nottingham And University Polymer microspheres and a method of production thereof
US5665428A (en) * 1995-10-25 1997-09-09 Macromed, Inc. Preparation of peptide containing biodegradable microspheres by melt process
US5702717A (en) * 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
JP3028227B1 (ja) 1998-12-15 2000-04-04 穎助 藤本 デスポーザル無針注射器

Also Published As

Publication number Publication date
CN1344755A (zh) 2002-04-17
EP1028137A2 (en) 2000-08-16
JPH09501967A (ja) 1997-02-25
FI960892A7 (fi) 1996-04-18
ATE327273T1 (de) 2006-06-15
EP1028137A3 (en) 2000-11-02
PT719295E (pt) 2006-10-31
HU9600456D0 (en) 1996-04-29
KR100341995B1 (ko) 2002-11-23
IL110787A0 (en) 1994-11-11
AU697995B2 (en) 1998-10-22
JP3343124B2 (ja) 2002-11-11
CN1258551C (zh) 2006-06-07
EP0719295A1 (en) 1996-07-03
US6262127B1 (en) 2001-07-17
NO20021141D0 (no) 2002-03-07
HU220637B1 (hu) 2002-03-28
SK25496A3 (en) 1997-03-05
CN1085687C (zh) 2002-05-29
CN1506116A (zh) 2004-06-23
WO1995006077A2 (en) 1995-03-02
AU7655794A (en) 1995-03-21
HUT74568A (en) 1997-01-28
WO1995006077A3 (en) 1995-05-04
NO960721D0 (no) 1996-02-23
JP4477813B2 (ja) 2010-06-09
EP0719295B1 (en) 2006-05-24
PL312717A1 (en) 1996-05-13
CZ55296A3 (en) 1996-09-11
NO960721L (no) 1996-04-26
ES2262135T3 (es) 2006-11-16
US6083521A (en) 2000-07-04
SG87847A1 (en) 2002-04-16
NZ273319A (en) 1998-02-26
TW492863B (en) 2002-07-01
PL182569B1 (pl) 2002-01-31
DE69434743D1 (de) 2006-06-29
JP2003002844A (ja) 2003-01-08
CA2168012A1 (en) 1995-03-02
BR9407370A (pt) 1996-07-16
CN1326568C (zh) 2007-07-18
FI960892A0 (fi) 1996-02-26
CA2168012C (en) 2005-08-09
NO20021141L (no) 1996-04-26
DE69434743T2 (de) 2006-11-16
SG50724A1 (en) 1999-10-19
CN1129947A (zh) 1996-08-28
DK0719295T3 (da) 2006-09-25

Similar Documents

Publication Publication Date Title
FI960892L (fi) Polymeerimatriisit ja niiden käyttö farmaseuttisissa koostumuksissa
FI955226A0 (fi) Polymeerikoostumuksia ja niiden valmistus, erityisesti absorptiomateriaaleja sekä niiden käyttö
BR1100824A (pt) Composto e composição farmacêutica
FI943569L (fi) Hyviä liukenemisominaisuuksia omaavia farmaseuttisia koostumuksia
FI941747L (fi) Koostumuksia ja niiden käyttöjä
FI962589L (fi) 2,4-disulfofenyylibutyylinitroni, sen suolat ja niiden käyttö farmaseuttisina aineina
FI955228A0 (fi) Polymeerikoostumus, absorptiomateriaalikoostumus, niiden valmistus ja niiden käyttö
DE69618587D1 (de) Chinazoline und pharmazeutische zusammensetzungen
DK1023900T3 (da) Farmaceutisk præparat indeholdende S-nitroso-lipoproteiner og anvendelse deraf
FI955227A7 (fi) Polymeerikoostumus, absorptiomateriaalikoostumus, niiden valmistus ja niiden käyttö
FI944832A7 (fi) Farmaseuttinen koostumus
FI955140L (fi) Uusia kinoksaliinidionijohdannaisia, niiden valmistus ja käyttö lääkkeissä
FI953478L (fi) Stabiileja nestemäisiä koostumuksia ja niiden käyttö
ITMI932540A0 (it) Composizione farmaceutica
BR9509688A (pt) Composto e composição farmacêutica
FI934325A7 (fi) Hyönteismyrkkykoostumus ja hyönteismyrkky-yksiköitä
DE69434210D1 (de) Pharmazeutische antacidzusammensetzung
FI960487L (fi) Bentsopyraaneja ja niitä sisältäviä farmaseuttisia koostumuksia
FI901095A7 (fi) Polymeerirakeita ja niitä sisältäviä koostumuksia
EE9400337A (et) Alfainterferooni sisaldavad farmatseutilised kompositsioonid ja nende kasutusvõimalused
LV10579A (lv) Farmaceitiska kompozicija
AU3752189A (en) Pharmaceutical compositions and use thereof in treating inflammation
DE69130611D1 (de) Hydroxycholesterol enthaltende pharmazeutsiche zusammensetzungen und deren verwendung in medikamenten
FI950285A7 (fi) Polymeerikoostumuksia ja menetelmiä
ZA946536B (en) Polymeric matrices and their uses in pharmaceutical compositions

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: NOVARTIS AG